Status:

COMPLETED

Eight Week Primaquine Regimen for the Treatment of Vivax Malaria

Lead Sponsor:

London School of Hygiene and Tropical Medicine

Collaborating Sponsors:

HealthNet TPO

Conditions:

Malaria

Vivax Malaria

Eligibility:

All Genders

3-70 years

Phase:

PHASE3

Brief Summary

Plasmodium vivax represents a major health problem throughout the tropics. Outside Africa it accounts for over 50% of cases, affecting an estimated 70-80 million people per year. A substantial proport...

Detailed Description

Old evidence suggests that successful PQ therapy is not a function of the length of the course of treatment, nor the circulating concentration of the drug, but of the total dosage administered. The sa...

Eligibility Criteria

Inclusion

  • Patients diagnosed with P. vivax parasitaemia
  • Patients over 3 years
  • Patients with G6PD deficiency to a safety trial
  • Patients without G6PD deficiency to all other groups.

Exclusion

  • Children under the age of three
  • Pregnant / breast feeding women
  • Patients with severe clinical anaemia \[Hb\<7g/dl\]
  • Patients with P. falciparum
  • Patients unavailable for the duration of study.
  • Patients who have taken antimalarial drugs in the 2 weeks prior to consultation.
  • Patients with concomitant infections or whose general health is considered too poor.

Key Trial Info

Start Date :

April 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

March 1 2007

Estimated Enrollment :

150 Patients enrolled

Trial Details

Trial ID

NCT00158587

Start Date

April 1 2004

End Date

March 1 2007

Last Update

January 12 2017

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.